Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the Company, we, us, or
our) within the meaning of the federal securities laws, including those related to the Companys expectations of timing and potential results of the clinical trials and other development activities of the Company and its partners;
the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Companys small-molecule product candidates; the potential for the mechanisms of action of the Companys
product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Companys product candidates in their targeted indications, including the clinical utility of the data from and the endpoints
used in the Companys clinical trials; the Companys clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Companys expectations regarding the profile of
its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Companys plans for and ability to continue
to execute on its current development strategy, including potential combinations involving multiple product candidates; the impact of new legislation and regulatory developments on the Companys plans for its product candidates, such as the
effect of the Inflation Reduction Act of 2022; and the Companys expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release,
including statements regarding the Companys strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements.
In some cases, you can identify forward-looking statements by terminology such as aim, anticipate, assume, believe, contemplate, continue, could, design,
due, estimate, expect, goal, intend, may, objective, plan, positioned, potential, predict, seek,
should, target, will, would and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The
Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations,
business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and
uncertainties that could cause the actual results and the implementation of the Companys plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Companys current
and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Companys actual results, please refer to the risk
factors identified in the Companys SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2022. Except as required by law, the Company undertakes no
obligation to update publicly any forward-looking statements for any reason.
Contacts for Terns
Investors
Mark Vignola
investors@ternspharma.com